Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 4
2017 6
2018 6
2019 6
2020 6
2021 5
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death.
Rosenbaum SR, Caksa S, Stefanski CD, Trachtenberg IV, Wilson HP, Wilski NA, Ott CA, Purwin TJ, Haj JI, Pomante D, Kotas D, Chervoneva I, Capparelli C, Aplin AE. Rosenbaum SR, et al. Mol Cancer Res. 2024 Feb 1;22(2):209-220. doi: 10.1158/1541-7786.MCR-23-0290. Mol Cancer Res. 2024. PMID: 37847239
MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping.
Filipescu D, Carcamo S, Agarwal A, Tung N, Humblin É, Goldberg MS, Vyas NS, Beaumont KG, Demircioglu D, Sridhar S, Ghiraldini FG, Capparelli C, Aplin AE, Salmon H, Sebra R, Kamphorst AO, Merad M, Hasson D, Bernstein E. Filipescu D, et al. Nat Cell Biol. 2023 Sep;25(9):1332-1345. doi: 10.1038/s41556-023-01208-7. Epub 2023 Aug 21. Nat Cell Biol. 2023. PMID: 37605008 Free PMC article.
Targeting TEAD-ious resistance.
Ott CA, Aplin AE. Ott CA, et al. Trends Cancer. 2023 Oct;9(10):780-781. doi: 10.1016/j.trecan.2023.07.016. Epub 2023 Aug 3. Trends Cancer. 2023. PMID: 37543514
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.
Glasheen MQ, Caksa S, Young AG, Wilski NA, Ott CA, Chervoneva I, Flaherty KT, Herlyn M, Xu X, Aplin AE, Capparelli C. Glasheen MQ, et al. Mol Cancer Ther. 2023 Sep 5;22(9):1087-1099. doi: 10.1158/1535-7163.MCT-23-0025. Mol Cancer Ther. 2023. PMID: 37343247 Free PMC article.
Site matters in metastatic melanoma.
Wilson HP, Aplin AE. Wilson HP, et al. Trends Cancer. 2023 Aug;9(8):603-605. doi: 10.1016/j.trecan.2023.05.007. Epub 2023 Jun 17. Trends Cancer. 2023. PMID: 37331825 Free PMC article.
Packing a Punch against PD-L1.
Capparelli C, Aplin AE. Capparelli C, et al. Cancer Discov. 2022 Jun 2;12(6):1413-1415. doi: 10.1158/2159-8290.CD-22-0301. Cancer Discov. 2022. PMID: 35652219
The future of targeted kinase inhibitors in melanoma.
Caksa S, Baqai U, Aplin AE. Caksa S, et al. Pharmacol Ther. 2022 Nov;239:108200. doi: 10.1016/j.pharmthera.2022.108200. Epub 2022 May 2. Pharmacol Ther. 2022. PMID: 35513054 Free PMC article. Review.
40 results